Prostate cancer survival benefit shown by Janssen-Cilag's Zytiga plus prednisone

14 March 2016

New data from Janssen-Cilag, a subsidiary of US health care giant Johnson & Johnson (NYSE: JNJ), shows increased survival rates among men with early and less aggressive metastatic castration-resistant prostate cancer using Zytiga (abiraterone acetate) plus prednisone.

Data from the post-hoc analysis of the Phase III COU-AA-302 trial was presented on Monday at the European Association of Urology (EAU) 2016 Congress in Germany.

This showed that those treated with Zytiga plus prednisone survived on average 53.6 months, 11.8 months longer than those given an active control of placebo plus prednisone.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK